Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

Vytorin/Zetia Securities Litigation

Merck shareholders filed a class-action lawsuit alleging that Merck, Merck/Schering-Plough Pharmaceuticals, MSP Distribution Services, and MSP Singapore Company violated federal securities laws by failing to disclose material information and making false and misleading statements about the commercial prospects of the cholesterol drug Vytorin (a combination of the Merck drug Zocor and the Schering-Plough drug Zetia) between 2006 and 2008. They claimed that the defendants concealed the results of a clinical test (known as the “ENHANCE” study) that showed Vytorin was no more effective than Zocor alone. In June 2013, the lawsuit was settled for $215 million. See related Merck instances, “ENHANCE Securities Litigation” and “Vytorin Multistate Investigation”.

Misconduct Type
Securities
Enforcement Agency
Non-Governmental
Contracting Party
None
Court Type
Civil
Disposition
Settlement
Date of Settlement
6/3/2013
Contractors Involved Penalty
Total
Merck & Co., Inc. $215,000,000
Further Information Released
Settlement Agreement 6/3/2013
Second Amended Complaint 2/9/2012

See also:

Federal Contractor Misconduct Database